Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
Feb 4, 2021 --Multiple Clinical Development Milestones Anticipated in 2021--
|
Jan 4, 2021 - Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies -
|
Nov 10, 2020 --Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment--
|
Sep 9, 2020 - Strong cash position of ~$183 million at start of fiscal year 2021 -
|
Jul 2, 2020 Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
|
May 26, 2020 - Event scheduled for June 2, 2020 at 8am ET; featuring leading KOL Matthew Matasar, M.D. -
|
